Drugs / ABT-639
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01589432 | Apr → Nov 2012 | diabetic polyneuropathy | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01345045 | Apr → Oct 2011 | diabetic polyneuropathy | AbbVie | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABT-639 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01345045 ↗ |
| Known as | Abt-639 free base | ChEMBL registry synonym — accepted as the source's own label CHEMBL3590674 ↗ |
| Action | Inhibit | “a peripherally acting highly selective T-type Cav3.2 calcium channel blocker” PMID 26067585 ↗ Oct 20151“Voltage-gated T-type calcium channel alpha-1H subunit blocker” CHEMBL3590674 ↗ |
| Modality | Small molecule | — CHEMBL3590674 ↗ |
| Route | Oral | “single 100-mg oral dose of ABT-639” PMID 26035253 ↗ Nov 2015 |
| Target | CACNA1H | “Voltage-gated T-type calcium channel alpha-1H subunit blocker” CHEMBL3590674 ↗ |